JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer

  NCT04149496

  Condition:   Polycystic Ovary Syndrome
  Intervention:   Combination Product: in vitro maturation of oocytes
  Sponsor:   Bruce Rose, MD
  Recruiting
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (an Autoimmune Disorder That Destructs Platelets, Blood Cells That Help With Clotting, and Can Lead to Easy or Excessive Bruising and Bleeding)

  NCT04188379

  Condition:   Primary Immune Thrombocytopenia
  Interventions:   Biological: efgartigimod;   Other: Placebo
  Sponsor:   argenx BVBA
  Recruiting
• Biorepository of Biomarkers for Optimization of Microvascular Treatment of Lymphedema

  NCT04123457

  Condition:   Lymphedema
  Intervention:  
  Sponsor:   Mayo Clinic
  Recruiting
• Globus Pallidus Stimulation to Treat Insomnia

  NCT04116996

  Condition:   Parkinson Disease
  Intervention:   Device: DEEP BRAIN STIMULATION
  Sponsor:   Mayo Clinic
  Recruiting
• Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine

  NCT04068051

  Condition:   Migraine
  Intervention:   Drug: AXS-07
  Sponsor:   Axsome Therapeutics, Inc.
  Recruiting
• Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

  NCT04047810

  Condition:   Chronic Obstructive Pulmonary Disease
  Intervention:   Biological: Mesenchymal Stem Cells
  Sponsor:   Mayo Clinic
  Recruiting
• Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation

  NCT04046731

  Condition:   Allergy
  Intervention:   Diagnostic Test: Skin Testing
  Sponsor:   Mayo Clinic
  Recruiting
• Open-Label Safety Study of AXS-05 in Subjects With Depression

  NCT04039022

  Conditions:   Major Depressive Disorder;   Treatment Resistant Depression;   Depression
  Intervention:   Drug: AXS-05
  Sponsor:   Axsome Therapeutics, Inc.
  Recruiting
• Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty

  NCT04028947

  Condition:   Knee Pain Chronic
  Intervention:   Procedure: Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
  Sponsor:   Mayo Clinic
  Recruiting
• Platelet-Rich Fibrin in Intraoral Soft Tissue Regeneration

  NCT04022720

  Condition:   Mucosal Ulceration
  Intervention:   Procedure: Platelet Rich Fibrin Application
  Sponsor:   University of Florida
  Recruiting
• Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

  NCT04006288

  Condition:   Coronary Artery Disease
  Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: ticagrelor;   Drug: aspirin;   Drug: rivaroxaban
  Sponsors:   University of Florida;   Janssen, LP
  Recruiting
• Early Active Controlled Motion (EACM) Rehabilitation Protocol Post Open Reduction and Internal Fixation (ORIF) of Scaphoid Fractures: A Pilot Study

  NCT03996512

  Condition:   Scaphoid Fixation
  Intervention:   Other: Early Active Controlled Motion (EACM)
  Sponsors:   University of Florida;   Performance Health
  Recruiting
• Functional Predictive Value of Collective Outcome Measure(s) Status Post Total Hip/Knee Arthroplasty

  NCT03933969

  Conditions:   Joint Arthroplasty;   Knee and Hip
  Intervention:  
  Sponsor:   Mayo Clinic
  Recruiting
• Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

  NCT03929120

  Conditions:   Interstitial Lung Disease;   Connective Tissue Diseases
  Intervention:   Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
  Sponsor:   Mayo Clinic
  Recruiting
• Development of a Risk Prediction Screening Tool for Opioid-Prescription Injury (STOP Injury) in Older Adults Initiated on Opioids From the Emergency Department

  NCT03836235

  Condition:   Opioid Use
  Intervention:  
  Sponsors:   University of Florida;   National Institute on Aging (NIA);   US Department of Health and Human Services
  Recruiting
• Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic

  NCT03828890

  Condition:   Diabetes Mellitus
  Intervention:   Diagnostic Test: Screening eye exam using Optos technology
  Sponsor:   Mayo Clinic
  Recruiting
• Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

  NCT03811873

  Conditions:   Metabolic Bone Disease;   Transplant-Related Disorder;   Secondary Osteoporosis
  Intervention:   Radiation: Thoracic spine X-Ray
  Sponsor:   Mayo Clinic
  Recruiting
• Treating Acute Pancreatitis With Dabigatran, a Pilot Study

  NCT03807856

  Condition:   Acute Pancreatitis
  Interventions:   Drug: Dabigatran Etexilate Mesylate;   Other: Standard of Care
  Sponsor:   Mayo Clinic
  Recruiting
• Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

  NCT03774394

  Conditions:   Chronic Kidney Disease (CKD);   Type 2 Diabetes Mellitus (T2DM);   Coronary Artery Disease (CAD)
  Interventions:   Drug: Clopidogrel;   Drug: Clopidogrel active metabolite
  Sponsor:   University of Florida
  Recruiting
• The Randomized OPTIMAL-ACT Trial

  NCT03772613

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Anticoagulant-induced Bleeding;   Coronary Syndrome
  Intervention:   Drug: Unfractionated heparin
  Sponsor:   Mayo Clinic
  Recruiting
• Stimulation to Enhance Walking Post-SCI

  NCT03702842

  Conditions:   SCI - Spinal Cord Injury;   Incomplete Spinal Cord Injury
  Interventions:   Device: Soterix Medical tsDCS stimulator;   Other: Locomotor training
  Sponsors:   University of Florida;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Brooks Rehabilitation
  Recruiting
• A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

  NCT03647917

  Condition:   Skin Aging of Face and Hands
  Intervention:   Biological: Platelet Rich Plasma
  Sponsor:   Mayo Clinic
  Recruiting
• Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

  NCT03624660

  Condition:   Adenocarcinoma of the Prostate
  Interventions:   Radiation: HR-A;   Radiation: HR-B;   Radiation: HR-C
  Sponsor:   University of Florida
  Recruiting
• Awake vs. Asleep Craniotomy for Non-eloquent Gliomas

  NCT03621748

  Condition:   Intracranial Glioma
  Interventions:   Procedure: Awake Anesthesia Protocol;   Procedure: Non-awake Anesthesia Protocol
  Sponsor:   Mayo Clinic
  Recruiting
• Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH

  NCT03611790

  Condition:   Cerebral Vasospasm
  Intervention:   Device: NeVa VS
  Sponsor:   Vesalio
  Recruiting
• Critical Care and Palliative Care Medicine Together in the ICU

  NCT03520023

  Conditions:   Palliative Care;   Intensive Care Unit;   Hospice
  Intervention:   Other: Palliative Care Consult
  Sponsor:   Mayo Clinic
  Recruiting
• Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)

  NCT03517852

  Condition:   Peritoneal Carcinomatosis
  Intervention:   Device: Human Intravital Microscopy
  Sponsor:   Mayo Clinic
  Recruiting
• Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

  NCT03494881

  Condition:   Chronic Spontaneous Urticaria
  Intervention:   Drug: Nucala
  Sponsors:   Mayo Clinic;   GlaxoSmithKline
  Recruiting
• Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy

  NCT03484039

  Conditions:   Epilepsy;   Seizure Disorder
  Interventions:   Behavioral: Medication Adherence;   Behavioral: Seizure Documentation;   Behavioral: Memory Improvement;   Behavioral: Stress Management
  Sponsors:   University of Florida;   Dupont Fund, Jesse Ball;   Florida Blue Foundation;   Riverside Hospital Foundation
  Recruiting
• Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

  NCT03437044

  Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease
  Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
  Sponsors:   University of Florida;   AstraZeneca
  Recruiting
• Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

  NCT03317795

  Conditions:   Heavy Menstrual Bleeding;   Menorrhagia;   Uterine Fibroids
  Interventions:   Drug: Levonorgestrel IUS;   Drug: Tranexamic Acid
  Sponsors:   Shannon K. Laughlin-Tommaso;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

  NCT03096288

  Condition:   Atherosclerotic Cardiovascular Disease
  Interventions:   Drug: Evolocumab;   Other: Placebo
  Sponsors:   University of Florida;   Amgen
  Recruiting
• Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds

  NCT02803164

  Condition:   Open Chest Wounds
  Intervention:   Device: Wound Vacuum-assisted dressing
  Sponsor:   Mayo Clinic
  Recruiting
• Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

  NCT02598349

  Condition:   Pancreatic Cancer
  Interventions:   Radiation: Proton Radiation;   Drug: Capecitabine;   Procedure: Surgical resection;   Behavioral: FACT-Hep questionnaire
  Sponsors:   Proton Collaborative Group;   University of Florida Health
  Recruiting
• Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques

  NCT02548546

  Condition:   Abdominal Aortic Aneurysm
  Interventions:   Device: ECHO;   Device: ECG-gated MRA
  Sponsor:   Mayo Clinic
  Recruiting
• Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

  NCT02539160

  Conditions:   Coronary Artery Disease;   Diabetes Mellitus
  Intervention:   Drug: ticagrelor
  Sponsor:   University of Florida
  Recruiting
• Negative Predictive Value and NIC of Beta-Lactam Antibiotics.

  NCT04126096

  Condition:   Allergy
  Intervention:   Diagnostic Test: Skin Testing
  Sponsor:   Mayo Clinic
  Recruiting
• Hypersensitivity Reactions During Anesthesia

  NCT04125420

  Condition:   Allergy
  Intervention:  
  Sponsor:   Mayo Clinic
  Recruiting
• Acupuncture Relief for Chronic Neck Pain

  NCT03859011

  Condition:   Neck Pain, Posterior
  Interventions:   Other: Acupuncture;   Other: Usual Care
  Sponsors:   University of Florida;   Utica College
  Recruiting
• Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy

  NCT02199366

  Condition:   Breast Cancer
  Intervention:   Procedure: Cardiac magnetic resonance (cardiac MRI)
  Sponsors:   University of Florida;   Ocala Royal Dames
  Recruiting
• Mesenchymal Stem Cell Therapy for Lung Rejection

  NCT02181712

  Conditions:   Lung Transplant Reject;   Bronchiolitis Obliterans
  Interventions:   Biological: Mesenchymal stem cell 0.5;   Biological: Mesenchymal stem cell 1.0
  Sponsor:   Mayo Clinic
  Recruiting
• Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  NCT00969111

  Condition:   Prostate Cancer
  Interventions:   Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE;   Radiation: Proton (prostate bed) to 70.2 CGE;   Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE;   Radiation: Proton to 66.6 CGE
  Sponsors:   Proton Collaborative Group;   University of Florida Health
  Recruiting
• A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  NCT04144023

  Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive
  Interventions:   Biological: Granulocyte-Macrophage Colony-Stimulating Factor;   Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension

  NCT04104490

  Condition:   Pulmonary Arterial Hypertension
  Intervention:  
  Sponsors:   University of Florida;   National Heart, Lung, and Blood Institute (NHLBI);   Mayo Clinic;   Federal University of Health Science of Porto Alegre
  Recruiting
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

  NCT03865212

  Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Metastatic Melanoma;   Metastatic Uveal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Unresectable Melanoma
  Intervention:   Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Preventing Lymphedema in Axillary Lymph Node Dissection

  NCT03428581

  Condition:   Lymphedema
  Interventions:   Procedure: ALND with ARM +/- LVB;   Procedure: ALND
  Sponsor:   Mayo Clinic
  Recruiting
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

  NCT03106415

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Binimetinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• TORUS 2 IDE Clinical Study

  NCT04130737

  Condition:   Peripheral Arterial Disease
  Intervention:   Device: TORUS Stent Graft System
  Sponsors:   PQ Bypass, Inc.;   Syntactx
  Recruiting
• Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain

  NCT03947749

  Conditions:   Pain, Chronic;   Prescription Drug Abuse (Not Dependent)
  Intervention:  
  Sponsors:   University of Florida;   Florida Medical Malpractice Joint Underwriting Association
  Recruiting
• Daily vs. Non-Daily SBRT for NSCLC

  NCT03624907

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Radiation: Daily Stereotactic Body Radiotherapy;   Radiation: Non-Daily Stereotactic Body Radiotherapy
  Sponsor:   University of Florida
  Recruiting
• Diaphragm Pacing After Spinal Cord Injury

  NCT02556125

  Condition:   Injuries, Spinal Cord
  Intervention:   Device: Diaphragm pacing
  Sponsors:   University of Florida;   Brooks Rehabilitation;   The Craig H. Neilsen Foundation
  Recruiting
• LIPIDS-P Trial Phase I/II

  NCT03405870

  Conditions:   Sepsis, Severe;   Septic Shock
  Intervention:   Drug: Smoflipid
  Sponsors:   University of Florida;   Fresenius Kabi
  Recruiting
• Enhancing School-Based Violence Prevention

  NCT04087772

  Condition:   Aggressive Childhood Behavior
  Interventions:   Behavioral: Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH);   Behavioral: Racial/Ethnic Discrimination Interventions (RED)
  Sponsors:   Medical University of South Carolina;   National Institute on Minority Health and Health Disparities (NIMHD)
  Recruiting
• Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

  NCT03960177

  Condition:   Osteosarcoma
  Intervention:   Drug: Glucarpidase
  Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
  Recruiting
• Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma

  NCT03554083

  Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: Vemurafenib
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Genentech, Inc.;   Stand Up To Cancer
  Recruiting
• Renuvion Dermal System for Dermal Resurfacing

  NCT04185909

  Conditions:   Wrinkle;   Rhytides
  Intervention:   Device: Renuvion Dermal System
  Sponsor:   Apyx Medical
  Recruiting
• Envarsus XR Compared to Immediate Release Tacrolimus

  NCT03979365

  Condition:   Kidney Transplant Recipients
  Interventions:   Drug: Envarsus XR;   Drug: Tacrolimus twice daily
  Sponsors:   Mayo Clinic;   Veloxis Pharmaceuticals
  Recruiting
• TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol

  NCT03879629

  Condition:   Breast Cancer
  Intervention:   Drug: Carvedilol
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Shared Decision Making to Improve Goals of Care in the ED

  NCT03833622

  Condition:   Goals
  Intervention:   Other: Shared Decision Aid Assessment
  Sponsor:   Mayo Clinic
  Recruiting
• Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT03516617

  Conditions:   CCND1 Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
  Interventions:   Drug: Acalabrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

  NCT03281902

  Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

  NCT03242824

  Condition:   Glioma
  Interventions:   Drug: Fluorine F 18 Fluorodopa;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Positron Emission Tomography
  Sponsor:   Mayo Clinic
  Recruiting
• FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer

  NCT03179904

  Conditions:   HER2 Positive Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
  Interventions:   Drug: FASN Inhibitor TVB-2640;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Delineating Swallowing Impairment and Decline in ALS

  NCT02962050

  Condition:   Amyotrophic Lateral Sclerosis
  Interventions:   Procedure: Videofluoroscopic Swallowing Study (VFSS);   Procedure: High Resolution Manometry;   Other: DIGEST;   Other: Penetration Aspiration Scale;   Other: Normalized Residue Ratio Scale;   Device: Voluntary Peak Cough Flow Testing;   Device: Iowa Oral Performance Instrument;   Drug: Capsaicin Challenge;   Device: Pulmonary Function Testing;   Other: Eating Assessment Tool 10;   Other: The Center for Neurologic Study Bulbar Function Scale
  Sponsors:   University of Florida;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02312245

  Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

  NCT01415882

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Janssen Scientific Affairs, LLC
  Recruiting
• The CO2RE® System for Vulvar Lichen Sclerosus

  NCT04148651

  Condition:   Vulvar Lichen Sclerosus
  Intervention:   Device: The CO2RE® System
  Sponsor:   Candela Corporation
  Recruiting
• Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

  NCT00670358

  Condition:   Lymphoma
  Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

  NCT01871766

  Condition:   Rhabdomyosarcoma
  Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane;   Drug: ^1^1C-methionine
  Sponsor:   St. Jude Children's Research Hospital
  Recruiting
• pRESET for Occlusive Stroke Treatment

  NCT03994822

  Conditions:   Brain Diseases;   Cardiovascular Diseases;   Central Nervous System Diseases;   Cerebrovascular Disorders;   Ischemia;   Nervous System Diseases;   Pathologic Processes;   Stroke, Ischemic;   Stroke, Acute;   Vascular Diseases
  Interventions:   Device: Mechanical Thrombectomy using the pRESET Thrombectomy device;   Device: Mechanical Thrombectomy using the Solitaire Revascularization Device
  Sponsor:   phenox Inc.
  Recruiting
• Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

  NCT03464916

  Condition:   Relapsed or Refractory Multiple Myeloma
  Intervention:   Biological: CAR2 Anti-CD38 A2 CAR-T Cells
  Sponsor:   Sorrento Therapeutics, Inc.
  Recruiting
• To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.

  NCT04155645

  Conditions:   Dyslipidemia;   Type 2 Diabetes
  Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
  Sponsors:   AstraZeneca;   Parexel
  Recruiting
• A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

  NCT03200704

  Conditions:   Breast Cancer;   Lymph Node Mapping;   Sentinel Lymph Node Biopsy
  Intervention:   Combination Product: IC2000 and SPY-PHI
  Sponsor:   Novadaq Technologies ULC, now a part of Stryker
  Recruiting
• P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

  NCT03077243

  Conditions:   Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
  Interventions:   Radiation: Intensity Modulated Radiotherapy (IMRT) - deintensified;   Radiation: Intensity Modulated Radiotherapy (IMRT) - standard;   Drug: Cisplatin (or alternative) - deintensified;   Drug: Cisplatin (or alternative) - standard;   Procedure: Assessment for surgical evaluation
  Sponsor:   UNC Lineberger Comprehensive Cancer Center
  Recruiting
• Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma

  NCT02560623

  Condition:   Barrett's Esophagus
  Intervention:   Device: Sponge capsule
  Sponsors:   Mayo Clinic;   Exact Sciences Corporation
  Recruiting
• AMPLATZER PFO Occluder Post Approval Study

  NCT03309332

  Conditions:   Stroke;   Patent Foramen Ovale
  Intervention:   Device: AMPLATZER™ PFO Occluder
  Sponsor:   Abbott Medical Devices
  Recruiting
• Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

  NCT04167696

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
  Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara
  Sponsor:   Celyad (formerly named Cardio3 BioSciences)
  Recruiting
• Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia

  NCT04073186

  Condition:   Visual Acuity
  Intervention:   Device: ACUVUE® OASYS with Transitions™
  Sponsor:   Johnson & Johnson Vision Care, Inc.
  Recruiting
• A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

  NCT03761095

  Condition:   Leiomyosarcoma
  Interventions:   Drug: PTC596;   Drug: Dacarbazine
  Sponsor:   PTC Therapeutics
  Recruiting
• Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

  NCT03624517

  Conditions:   Esophageal Varices;   Liver Cirrhoses;   Bleeding Esophageal Varices;   Upper Gastrointestinal Bleeding
  Intervention:   Drug: Octreotide
  Sponsors:   Medical University of South Carolina;   Ohio State University;   University of Texas Southwestern Medical Center;   University of Florida Health
  Recruiting
• Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

  NCT03459339

  Condition:   Barrett Esophagus
  Intervention:   Device: Tethered Capsule Endomicroscopy (TCE)
  Sponsors:   Massachusetts General Hospital;   Columbia University;   Mayo Clinic;   Kansas City Veteran Affairs Medical Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Recruiting
• DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

  NCT02772003

  Conditions:   Chronic Hepatitis;   Hepatitis C Infection
  Interventions:   Biological: DNA Plasmid Encoding Interleukin-12 INO-9012;   Biological: Electroporation-Mediated Plasmid DNA Vaccine Therapy;   Biological: HCV DNA Vaccine INO-8000;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   Inovio Pharmaceuticals
  Recruiting
• Efficacy and Safety of UGN-101 in Recurrent Patients

  NCT04006691

  Conditions:   Carcinoma;   Transitional Cell Carcinoma;   Transitional Cell Cancer of the Renal Pelvis and Ureter
  Intervention:   Drug: UGN-101 instillations
  Sponsor:   UroGen Pharma Ltd.
  Recruiting
• Pursuit: Real World Use of the Eclipse System

  NCT03940573

  Condition:   Fecal Incontinence
  Intervention:   Device: Eclipse Insert
  Sponsor:   Pelvalon, Inc.
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

  NCT03499353

  Condition:   Early Breast Cancer
  Intervention:   Drug: TALAZOPARIB
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

  NCT03814187

  Conditions:   ASCVD;   Elevated Cholesterol;   Heterozygous Familial Hypercholesterolemia;   Homozygous Familial Hypercholesterolemia
  Intervention:   Drug: Inclisiran Sodium
  Sponsor:   The Medicines Company
  Recruiting
• Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302

  NCT03635996

  Condition:   Paroxysmal Supraventricular Tachycardia
  Intervention:   Drug: Etripamil NS 70 mg
  Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
  Recruiting
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  NCT03574597

  Conditions:   Overweight;   Obesity
  Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301

  NCT03464019

  Condition:   Paroxysmal Supraventricular Tachycardia
  Interventions:   Drug: Etripamil;   Drug: Placebo;   Device: Aptar Pharma Nasal Spray
  Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
  Recruiting
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

  NCT03439254

  Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
  Sponsor:   Intercept Pharmaceuticals
  Recruiting
• Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  NCT02993406

  Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
  Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
  Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
  Recruiting
• Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

  NCT02793583

  Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

  NCT02630316

  Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
  Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
  Sponsor:   United Therapeutics
  Recruiting
• Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  NCT02179086

  Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
  Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

  NCT03585270

  Condition:   Aneurysmal Subarachnoid Hemorrhage
  Interventions:   Drug: Clazosentan;   Drug: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

  NCT03561220

  Condition:   Prostate Cancer
  Interventions:   Radiation: Standard of Care IMRT (Photon);   Radiation: Standard of Care Proton Therapy;   Radiation: Proton Arm 1: Standard Proton Therapy;   Radiation: Proton Arm 2: Hypofractionated Proton Therapy
  Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute
  Recruiting
• A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery

  NCT03689244

  Condition:   Chronic Thromboembolic Pulmonary Hypertension
  Interventions:   Drug: Selexipag;   Drug: Placebo
  Sponsor:   Actelion
  Recruiting
• Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

  NCT04142242

  Condition:   Meningococcal Infection (Healthy Volunteers)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Other: Blood sample
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT03431350

  Condition:   Prostatic Neoplasms, Castration-Resistant
  Interventions:   Drug: Niraparib 200 mg;   Drug: JNJ-63723283 240 mg;   Drug: JNJ-63723283 480 mg;   Drug: Abiraterone Acetate;   Drug: Prednisone
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Biological: Benralizumab;   Biological: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

  NCT03882970

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
  Sponsor:   Eli Lilly and Company
  Recruiting
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401

  Condition:   Coronary Heart Disease (CHD)
  Interventions:   Drug: Evolocumab;   Drug: Placebo
  Sponsor:   Amgen
  Recruiting
• NBP in Adult Patients With Acute Ischemic Stroke (AIS)

  NCT02905565

  Condition:   AIS
  Interventions:   Drug: NBP Softgel Capsules;   Drug: Placebo
  Sponsor:   CSPC-NBP Pharmaceutical Co., Ltd.
  Recruiting
• To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

  NCT03777059

  Condition:   Episodic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
  Sponsor:   Allergan
  Recruiting
• A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244

  Condition:   Prostatic Neoplasms
  Interventions:   Drug: Apalutamide;   Drug: Androgen Deprivation Therapy (ADT);   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

  NCT03689712

  Condition:   Oral Mucositis
  Interventions:   Drug: GC4419;   Drug: Placebo
  Sponsor:   Galera Therapeutics, Inc.
  Recruiting
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

  NCT03599622

  Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
  Interventions:   Drug: BMS-986165;   Other: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561090

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

  NCT03521934

  Condition:   Heart Failure-Type 2 Diabetes Mellitus
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

  NCT03510897

  Condition:   Cardiac Surgery
  Interventions:   Drug: QPI-1002;   Drug: Placebo
  Sponsor:   Quark Pharmaceuticals
  Recruiting
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD

  NCT03496623

  Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Inhaled treprostinil solution;   Drug: Placebo solution
  Sponsor:   United Therapeutics
  Recruiting
• Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

  NCT03417388

  Condition:   Coronary Artery Disease
  Interventions:   Drug: High dose potent statin;   Drug: ACE-I (lisinopril) or ARB (losartan);   Drug: Aspirin;   Behavioral: Lifestyle Counseling;   Behavioral: Quality of Life Questionnaires
  Sponsors:   University of Florida;   United States Department of Defense
  Recruiting
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease

  NCT03395184

  Condition:   Crohn's Disease
  Interventions:   Drug: Placebo PF-06651600;   Drug: Placebo PF-06700841;   Drug: PF-06651600;   Drug: PF-06700841
  Sponsor:   Pfizer
  Recruiting
• Hemodynamic-GUIDEd Management of Heart Failure

  NCT03387813

  Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure，Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
  Intervention:   Device: CardioMEMS™ HF System
  Sponsor:   Abbott Medical Devices
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

  NCT03383146

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• SPYRAL HTN-ON MED Study

  NCT02439775

  Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
  Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
  Sponsor:   Medtronic Vascular
  Recruiting
• DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

  NCT03115333

  Conditions:   Gliosarcoma;   Recurrent Glioblastoma
  Intervention:   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

  NCT03071692

  Conditions:   Type2 Diabetes;   Dyslipidemia
  Interventions:   Drug: K-877;   Drug: Placebo
  Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
  Recruiting
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  NCT03057977

  Condition:   Heart Failure
  Interventions:   Drug: Empagliflozin;   Drug: Placebo
  Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
  Recruiting
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  NCT03057951

  Condition:   Heart Failure
  Interventions:   Drug: Empagliflozin;   Drug: Placebo
  Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
  Recruiting
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  NCT02876835

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
  Sponsor:   GlaxoSmithKline
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

  NCT02403323

  Condition:   Crohn Disease
  Intervention:   Drug: Etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

  NCT02394028

  Condition:   Crohn Disease
  Interventions:   Drug: Etrolizumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Dimethyl Fumarate (DMF) Observational Study

  NCT02047097

  Condition:   Multiple Sclerosis
  Intervention:   Drug: dimethyl fumarate
  Sponsor:   Biogen
  Recruiting
• Connect® MDS/AML Disease Registry

  NCT01688011

  Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
  Intervention:  
  Sponsor:   Celgene
  Recruiting
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

  NCT00887146

  Condition:   Brain and Central Nervous System Tumors
  Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
  Recruiting
• Psoriasis Longitudinal Assessment and Registry (PSOLAR)

  NCT00508547

  Conditions:   Psoriasis;   Arthritis, Psoriatic
  Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

  NCT03895437

  Condition:   Diabetes Mellitus, Type 1
  Interventions:   Biological: TOL-3021;   Other: TOL-3021 Placebo
  Sponsor:   Tolerion, Inc.
  Recruiting
• Longitudinal Early-onset Alzheimer's Disease Study Protocol

  NCT03507257

  Conditions:   Early Onset Alzheimer Disease;   Alzheimer Disease;   Mild Cognitive Impairment
  Interventions:   Drug: Flortaucipir;   Drug: Florbetaben
  Sponsors:   Liana Apostolova;   Alzheimer's Therapeutic Research Institute;   National Institute on Aging (NIA);   Alzheimer's Association
  Recruiting
• Extravascular ICD Pivotal Study

  NCT04060680

  Conditions:   Tachycardia;   Ventricular Arrythmia
  Intervention:   Device: Defibrillation
  Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
  Recruiting
• PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

  NCT02730312

  Conditions:   Acute Myelogenous Leukemia;   B-cell Acute Lymphoblastic Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myeloid Leukemia, Blast Crisis
  Intervention:   Biological: XmAb14045
  Sponsors:   Xencor, Inc.;   ICON Clinical Research
  Recruiting
• Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

  NCT03642210

  Condition:   Menorrhagia
  Intervention:   Combination Product: Levonorgestrel 52 mg intrauterine system
  Sponsor:   Medicines360
  Recruiting
• Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

  NCT03951077

  Condition:   Polycystic Ovary Syndrome
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

  NCT02273362

  Conditions:   Cirrhosis;   Hepatocellular Carcinoma
  Interventions:   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

  NCT03572634

  Conditions:   Chronic Lymphocytic Leukemia;   CLL;   SLL;   Small Lymphocytic Lymphoma
  Interventions:   Drug: TP-0903;   Combination Product: TP-0903 and ibrutinib combination therapy
  Sponsor:   Tolero Pharmaceuticals, Inc.
  Recruiting
• Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450

  Conditions:   Cancer Survivor;   Osteosarcoma
  Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

  NCT03002805

  Condition:   Sarcoma
  Intervention:   Drug: CBT-1®
  Sponsor:   CBA Research
  Recruiting
• Study of DCC-3014 in Patients With Advanced Tumors

  NCT03069469

  Conditions:   Advanced Malignant Neoplasm;   Tenosynovial Giant Cell Tumor, Diffuse
  Intervention:   Drug: DCC-3014
  Sponsor:   Deciphera Pharmaceuticals LLC
  Recruiting
• A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

  NCT03129139

  Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach
  Intervention:   Drug: Minnelide™Capsules
  Sponsors:   Minneamrita Therapeutics LLC;   Translational Drug Development
  Recruiting
• Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

  NCT03903822

  Condition:   Atopic Dermatitis
  Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
  Sponsor:   Pfizer
  Recruiting
• OPsumit USers Registry

  NCT02126943

  Condition:   Pulmonary Arterial Hypertension
  Intervention:   Drug: Opsumit (macitentan)
  Sponsor:   Actelion
  Recruiting
• Cross-Seal Closure Device IDE Trial

  NCT03756558

  Condition:   Vascular Closure
  Intervention:   Device: Cross-Seal System
  Sponsor:   Terumo Medical Corporation
  Recruiting
• Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

  NCT03641677

  Condition:   Lung Diseases
  Interventions:   Device: Centralized Lung Evaluation System;   Procedure: Lung Transplant
  Sponsor:   Lung Bioengineering Inc.
  Recruiting
• Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

  NCT03533257

  Condition:   Alzheimer Disease
  Interventions:   Drug: AMX0035;   Drug: Placebo
  Sponsors:   Amylyx Pharmaceuticals Inc.;   Alzheimer’s Drug Discovery Foundation;   Alzheimer's Association
  Recruiting
• Treatment With Intent to Generate Endovascular Reperfusion

  NCT03474549

  Condition:   Ischemic Stroke
  Intervention:   Device: Tigertriever revascularization device
  Sponsor:   Rapid Medical
  Recruiting
• Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

  NCT03447990

  Conditions:   Dilated Cardiomyopathy;   Heart Failure With Reduced Ejection Fraction
  Intervention:   Drug: MYK-491
  Sponsor:   MyoKardia, Inc.
  Recruiting
• Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

  NCT03334409

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Ascorbic Acid;   Drug: Pazopanib Hydrochloride
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

  NCT03150420

  Condition:   Calciphylaxis
  Interventions:   Drug: Sodium Thiosulfate;   Drug: Placebo-Normal Saline
  Sponsor:   Hope Pharmaceuticals
  Recruiting
• INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

  NCT03037164

  Condition:   Anemia
  Interventions:   Device: INTERCEPT Blood System for Red Blood Cells;   Device: Conventional (Control)
  Sponsor:   Cerus Corporation
  Recruiting
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

  NCT02628405

  Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

  NCT03934216

  Condition:   Ulcerative Colitis
  Interventions:   Drug: BMS-986165;   Drug: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

  NCT03837327

  Conditions:   Adnexal Mass;   Ovarian Cancer;   Pelvic Mass
  Intervention:  
  Sponsor:   Venn Biosciences Corporation
  Recruiting
• Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

  NCT03654313

  Conditions:   Atherosclerosis;   Cardiovascular Disease
  Interventions:   Biological: MEDI6570;   Biological: Placebo;   Biological: Part B Placebo
  Sponsor:   MedImmune LLC
  Recruiting
• A Study of a Personalized Neoantigen Cancer Vaccine

  NCT03639714

  Conditions:   Non Small Cell Lung Cancer;   Colorectal Cancer;   Gastroesophageal Adenocarcinoma;   Urothelial Carcinoma
  Interventions:   Biological: GRT-C901;   Biological: GRT-R902;   Biological: nivolumab;   Biological: ipilimumab
  Sponsors:   Gritstone Oncology, Inc.;   Bristol-Myers Squibb
  Recruiting
• MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

  NCT03489525

  Condition:   Relapsed/Refractory Multiple Myeloma
  Interventions:   Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate);   Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
  Sponsor:   MedImmune LLC
  Recruiting
• The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

  NCT03487913

  Condition:   Autosomal Dominant Polycystic Kidney Disease
  Intervention:   Drug: Lixivaptan
  Sponsor:   Palladio Biosciences
  Recruiting
• Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03266692

  Conditions:   Multiple Myeloma;   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
  Interventions:   Biological: ACTR087;   Biological: SEA-BCMA
  Sponsors:   Unum Therapeutics Inc.;   Seattle Genetics, Inc.
  Recruiting
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

  NCT03230318

  Conditions:   Intrahepatic Cholangiocarcinoma;   Combined Hepatocellular and Cholangiocarcinoma
  Intervention:   Drug: derazantinib
  Sponsor:   Basilea Pharmaceutica
  Recruiting
• Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

  NCT01617161

  Condition:   Prostate Cancer
  Interventions:   Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
  Sponsors:   Massachusetts General Hospital;   University of Pennsylvania;   National Cancer Institute (NCI);   Northwestern Medicine Chicago Proton Center;   ProCure Proton Therapy Center;   Washington University School of Medicine;   University of Washington;   Rutgers Cancer Institute of New Jersey;   Provision Center for Proton Therapy;   Mayo Clinic;   University of Maryland, College Park;   University Hospitals Cleveland Medical Center;   University of Florida Proton Therapy Institute
  Recruiting
• A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

  NCT03054870

  Condition:   Lung Structure Determination
  Interventions:   Drug: Xe-133;   Drug: Technegas
  Sponsor:   Cyclomedica Australia PTY Limited
  Recruiting
• Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

  NCT03030222

  Condition:   Heart Failure
  Interventions:   Drug: Empagliflozin 10Mg Tab;   Drug: Placebo Oral Tablet
  Sponsor:   Saint Luke's Health System
  Recruiting
• Trident II Tritanium Acetabular Shell Outcomes Study

  NCT02999009

  Condition:   Arthroplasty, Replacement, Hip
  Intervention:   Device: Trident II Tritanium Acetabular Shell
  Sponsor:   Stryker Orthopaedics
  Recruiting
• Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

  NCT02962895

  Condition:   Primary Sjogren's Syndrome
  Interventions:   Biological: VAY736;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)

  NCT02952508

  Conditions:   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   Mantle-Cell Lymphoma;   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: CLR 131 single dose;   Drug: CLR 131 multiple dose
  Sponsor:   Cellectar Biosciences, Inc.
  Recruiting
• Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer

  NCT02945579

  Conditions:   Estrogen Receptor Negative;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
  Interventions:   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Whole Breast Irradiation
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

  NCT02924402

  Conditions:   B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Intervention:   Biological: XmAb13676
  Sponsors:   Xencor, Inc.;   Chiltern International Inc.
  Recruiting
• Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

  NCT02807272

  Condition:   Leukemia, Myelomonocytic, Chronic
  Intervention:   Drug: Tipifarnib
  Sponsor:   Kura Oncology, Inc.
  Recruiting
• Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

  NCT02633059

  Conditions:   Loss of Chromosome 17p;   Recurrent Plasma Cell Myeloma
  Interventions:   Drug: Dexamethasone;   Drug: Idasanutlin;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

  NCT02361346

  Conditions:   Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Blood Cancer;   Hematological Malignancy
  Interventions:   Drug: MT-3724 Phase 1;   Drug: MT-3724 Phase 2
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

  NCT04041284

  Conditions:   Migraine;   Major Depressive Disorder
  Interventions:   Drug: Fremanezumab;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704

  Conditions:   Small Cell Lung Cancer;   Non-small Cell Lung Cancer, Squamous;   Non-small Cell Lung Cancer, Non-squamous;   Head and Neck Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
  Intervention:   Drug: ladiratuzumab vedotin
  Sponsor:   Seattle Genetics, Inc.
  Recruiting
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

  NCT03980730

  Condition:   Alzheimer Disease
  Interventions:   Drug: Azeliragon;   Drug: Placebo
  Sponsor:   vTv Therapeutics
  Recruiting
• A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

  NCT03955939

  Condition:   Metastatic Breast Cancer
  Interventions:   Drug: LY3295668 Erbumine;   Drug: Endocrine therapy;   Drug: Midazolam
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

  NCT03872206

  Condition:   Advanced Cancers Associated With Mesothelin Expression
  Intervention:   Biological: HPN536
  Sponsor:   Harpoon Therapeutics
  Recruiting
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03859427

  Condition:   Relapsed or Refractory Multiple Myeloma
  Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
  Sponsor:   Amgen
  Recruiting
• Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

  NCT03853694

  Conditions:   Elective Cesarean Section;   Pain Management
  Interventions:   Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen;   Drug: 150 mcg Duramorph + multi-modal pain regimen;   Drug: Exparel TAP + multi-modal pain regimen
  Sponsor:   Pacira Pharmaceuticals, Inc
  Recruiting
• Florida Pancreas Collaborative Next Generation Biobank

  NCT03851133

  Conditions:   Pancreatic Cancer;   Cancer Cachexia
  Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
  Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• Triathlon® Partial Knee Replacement (PKR) Outcomes Study

  NCT00966979

  Condition:   Arthroplasty, Replacement, Knee
  Intervention:   Device: Triathlon PKR
  Sponsor:   Stryker Orthopaedics
  Recruiting
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379

  Conditions:   Amyloidosis, Hereditary;   Transthyretin Amyloidosis
  Interventions:   Drug: Patisiran;   Drug: Vutrisiran (ALN-TTRSC02)
  Sponsor:   Alnylam Pharmaceuticals
  Recruiting
• Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

  NCT03757949

  Condition:   Bladder Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Nutritional Intervention;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Dominantly Inherited Alzheimer Network (DIAN)

  NCT00869817

  Condition:   Alzheimer's Disease
  Intervention:  
  Sponsors:   Washington University School of Medicine;   National Institute on Aging (NIA)
  Recruiting
• A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

  NCT03649971

  Condition:   Adenomatous Polyposis Coli
  Interventions:   Drug: Guselkumab;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

  NCT03593681

  Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Ovarian Neoplasms;   Ovary Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Adenocarcinoma;   High Grade Serous Carcinoma;   Peritoneal Carcinoma;   Peritoneal Neoplasms;   Adnexal Mass;   Ovarian Diseases
  Intervention:   Device: Hysteroscopic cell sampling of the fallopian tube
  Sponsors:   nVision Medical;   Boston Scientific Corporation
  Recruiting
• The SHUNT-V Study for Varices

  NCT03583996

  Condition:   Chronic Liver Disease
  Intervention:   Combination Product: HepQuant SHUNT Liver Diagnostic Test
  Sponsor:   HepQuant, LLC
  Recruiting
• A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03539744

  Condition:   Multiple Myeloma
  Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Venetoclax
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565

  Condition:   Multiple Myeloma
  Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

  NCT03288480

  Condition:   Multiple Myeloma
  Intervention:   Drug: PT-112
  Sponsor:   Phosplatin Therapeutics
  Recruiting
• A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma

  NCT03287908

  Condition:   Relapsed/Refractory Multiple Myeloma
  Intervention:   Drug: AMG 701
  Sponsor:   Amgen
  Recruiting
• Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

  NCT01696721

  Condition:   Pediatric Patients Treated With Radiation Therapy
  Intervention:   Other: No intervention
  Sponsor:   Massachusetts General Hospital
  Recruiting
• A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

  NCT03215706

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cisplatin
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

  NCT03194542

  Conditions:   Primary Myelofibrosis;   Anemia
  Intervention:   Drug: Luspatercept
  Sponsor:   Celgene
  Recruiting
• Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

  NCT03080883

  Conditions:   Cerebral Vein Thrombosis;   Deep Vein Thrombosis;   Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Pulmonary Embolism;   Splanchnic Vein Thrombosis
  Intervention:   Drug: Apixaban
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

  NCT03038672

  Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  Interventions:   Biological: Nivolumab;   Drug: Varlilumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

  NCT03030235

  Condition:   Chronic Heart Failure With Preserved Systolic Function
  Interventions:   Drug: Dapagliflozin 10Mg Oral Tablet;   Drug: Dapagliflozin matching placebo
  Sponsor:   Saint Luke's Health System
  Recruiting